365NEWSX
365NEWSX
Subscribe

Welcome

Ketamine, a New Depression Treatment, May Be Addictive, Some Fear - Business Insider

Ketamine, a New Depression Treatment, May Be Addictive, Some Fear - Business Insider

Ketamine, a New Depression Treatment, May Be Addictive, Some Fear - Business Insider
Jan 25, 2023 1 min, 13 secs

Things came to a head one night at Burning Man when, mixing ketamine with cannabis, he had a psychotic break and flew into a violent rage, smashing his face and arm through a glass mirror, despite his girlfriend's unsuccessful attempts to restrain him.

In February 2022, a (fairly small) double-blind trial published in The BMJ suggested that ketamine"rapidly induces remission of severe suicidal ideation in adults," with effects lasting more than six weeks in most patients.

Coveteur, a site known for tours of celebrities' closets, did a story on Field Trip Health, the trendy ketamine startup that plans to open 75 clinics by 2024, featuring glossy photos of rooms strewn with rose petals and Tibetan singing bowls.

A 2021 article in the American Journal of Psychiatry noted that the "opportunity and hope" ketamine provides "exist alongside the urgent need to clarify the long-term efficacy of these agents, as well as significant unanswered questions with respect to safety."

In 2021, another article in New York magazine helped readers choose which clinic was best for them as though they were picking a restaurant for date night, with tips like " Field Trip and Nushama are ideal for anxious first-timers" and "If you don't have a psychiatrist, try Mindbloom."

Spravato, the esketamine nasal spray patented by Janssen Pharmaceuticals, is overseen by an FDA drug-safety program called Risk Evaluation and Mitigation Strategy, meaning it has to be used in a doctor's office and is available only for those who have tried oral antidepressants.

Summarized by 365NEWSX ROBOTS

RECENT NEWS

SUBSCRIBE

Get monthly updates and free resources.

CONNECT WITH US

© Copyright 2024 365NEWSX - All RIGHTS RESERVED